DOCSLIB.ORG

Study of the Cytotoxic Activity and Immunogenicity of the Differentiated Morphotypes of the Genus Mycobacterium, in Relation with Their Cell Wall Composition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Study of the Cytotoxic Activity and Immunogenicity of the Differentiated Morphotypes of the Genus Mycobacterium, in Relation with Their Cell Wall Composition ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en Study of the cytotoxic activity and immunogenicity of the differentiated morphotypes of the genus Mycobacterium, in relation with their cell wall composition. by Marta Llorens Fons Directed by Dr. Marina Luquín Fernández Department of Genetics and Microbiology Universitat Autònoma de Barcelona February, 2018 Study of the cytotoxic activity and immunogenicity of the differentiated morphotypes of the genus Mycobacterium, in relation with their cell wall composition. by Marta Llorens Fons Thesis submitted to obtain the degree of Doctor of Philosophy in Microbiology, from the Department of Genetics and Microbiology by Universitat Autònoma de Barcelona. With the approval of the director and supervisor Dr. Marina Luquín Fernández Bellaterra, February, 2018 A tots aquells que conscientment o inconscient heu aportat el vostre granet de sorra. Però, sobretot, a l’Oriol i al Jaume, els homes més bons del món. Gràcies! Hold your breath, Paulina Siniatkina. Painting exhibited at the headquarters of the World Health Organization (WHO) in Geneva, March 2017. Paulina Siniatkina is a Russian artist who suffered of tuberculosis in 2015 and she created this collection of painting to fight the stigma attached to this disease. “People who are not infected react aggressively: they blame and avoid communication with those ill with tuberculosis. As a result, tuberculosis patients are afraid to speak out and they hide or lie about what is actually happening to them. As long as people are afraid to talk about it, this disease will continue to spread.” Index of Content Abstract........................................................................................................................................................ XI Resum ........................................................................................................................................................ XIII Abbreviations ........................................................................................................................................... XV 1. Introduction .......................................................................................................................................... 1 1.1. Mycobacteria and their diseases ............................................................................................. 3 1.2. Pulmonary tuberculosis .......................................................................................................... 15 1.3. Mycobacterial cell wall ............................................................................................................. 21 1.4. Mycobacterium vaccae and the vaccine against tuberculosis ................................... 33 2. Objectives............................................................................................................................................ 37 3. Material and methods .................................................................................................................... 41 3.1. Initial preparations .................................................................................................................... 43 3.2. Cell-based in vitro models ...................................................................................................... 45 3.3. Biochemist analysis ................................................................................................................... 50 3.4. Electronic microscopy .............................................................................................................. 53 3.5. Microbiologic methods ............................................................................................................ 55 4. Results .................................................................................................................................................. 59 4.1. Effect of M. abscessus in pulmonary epithelial cells ...................................................... 61 4.2. The most superficial lipids in M. abscessus cell wall ..................................................... 65 4.3. Study of the toxicity and function of TPP .......................................................................... 74 4.4. Superficial extraction in other Mycobacteria .................................................................. 81 4.5. Cellular response to the different morphotypes of M. vaccae .................................. 91 5. Discussion ...........................................................................................................................................97 6. Conclusions ...................................................................................................................................... 107 7. Bibliography .................................................................................................................................... 111 8. Manuscripts of this thesis .......................................................................................................... 131 Abstract Mycobacterium is a genus of microorganisms that comprise important human pathogens, such as the etiological agent of tuberculosis, Mycobacterium tuberculosis. Many mycobacterial species present two differentiated morphotypes, the rough (R) one characterized by bacillar organization in structures that reassemble cords; and the smooth (S) one without any bacillar aggregation. In pathogenic mycobacteria, R morphotypes are shown to produce more severe illnesses in infected patients than S morphotypes. In fact, this relationship between virulence and cord formation is known since 1947. Studying how bacteria aggregate will help to understand the different virulence associated to the two morphotypes of mycobacteria. The thesis here presented consists on the study of the cytotoxicity and immunogenicity of these two differentiated morphotypes, the R with a cording phenotype and the S with a non-cording phenotype, in Mycobacterium abscessus and Mycobacterium vaccae. And, in the case of M. abscessus, how these effects in virulence and the cord formation can be related to its cell wall composition. The two morphotypes of M. abscessus were used to infect human alveolar epithelial cells, and the ones from M. vaccae, in murine macrophages. The results, in both cases, showed that R morphotypes have major effect in suppressing cellular growth and a higher capacity to trigger cytokine production than S morphotypes. Superficial lipidic extractions were performed in M. abscessus, as the virulence and the cord formation might be related with the expression of determinate external cell wall components. Trehalose polyphleates (TPP) were identified in the superficial extracts from R morphotypes of M. abscessus, but TPP were absent in S morphotype extracts. Although this compound was not cytotoxic for human and murine cells, TPP presented aggregative potential. When analyzing the superficial expression of TPP in other mycobacterial species, another superficial compound, mycolate ester wax, was detected in Mycobacterium smegmatis, with a similar migration pattern to TPP. In this work, this compound was clearly characterized as pentatriacontatrienyl mycolate, as some uncertainties regarding its structure were previously reported. XI In conclusion, R morphotypes from M. abscessus and M. vaccae produced a major cytotoxic effect and major immunogenicity that S morphotypes in cell-based in vitro models. In the case of M. abscessus, this major virulence was accompanied with the superficial expression of TPP, a compound with aggregative properties. These last results point TPP as candidate molecules responsible for the cord formation in R morphotypes of M. abscessus. XII Resum Mycobacterium és un gènere de microorganismes que compren importants patògens de la humanitat, com l’agent etiològic de la tuberculosis, Mycobacterium tuberculosis. Moltes espècies de micobacteris presenten dos morfotips diferenciats, el rugós (R, de l’anglès “rough”) caracteritzat per la capacitat dels bacteris d’organitzar- se formant estructures que recorden cordes; i el llis (S, de l’anglès “smooth”) sense organització dels bacils. En micobacteris patògens s’ha descrit que els morfotips R produeixen malalties més severes en pacients infectats que els morfotips S. De fet, la relació entre virulència i formació de cordes es coneix des de 1947. De manera que estudiar com els bacteris s’agreguen ajudarà a entendre aquesta diferència entre la virulència associada als dos morfotips de micobacteris. La tesi presentada a continuació consisteix en un estudi de la citotoxicitat i la immunogenicitat d’aquests dos morfotips diferenciats, el R amb fenotip formador de cordes i el S amb fenotip no formador de cordes, en Mycobacterium abscessus i Mycobacterium vaccae. I, en el cas de M. abscessus, com aquests efectes en la virulència i la formació de cordes pot estar relacionat amb
Load more

Recommended publications
  • S1 Sulfate Reducing Bacteria and Mycobacteria Dominate the Biofilm
    Sulfate Reducing Bacteria and Mycobacteria Dominate the Biofilm Communities in a Chloraminated Drinking Water Distribution System C. Kimloi Gomez-Smith 1,2 , Timothy M. LaPara 1, 3, Raymond M. Hozalski 1,3* 1Department of Civil, Environmental, and Geo- Engineering, University of Minnesota, Minneapolis, Minnesota 55455 United States 2Water Resources Sciences Graduate Program, University of Minnesota, St. Paul, Minnesota 55108, United States 3BioTechnology Institute, University of Minnesota, St. Paul, Minnesota 55108, United States Pages: 9 Figures: 2 Tables: 3 Inquiries to: Raymond M. Hozalski, Department of Civil, Environmental, and Geo- Engineering, 500 Pillsbury Drive SE, Minneapolis, MN 554555, Tel: (612) 626-9650. Fax: (612) 626-7750. E-mail: [email protected] S1 Table S1. Reference sequences used in the newly created alignment and taxonomy databases for hsp65 Illumina sequencing. Sequences were obtained from the National Center for Biotechnology Information Genbank database. Accession Accession Organism name Organism name Number Number Arthrobacter ureafaciens DQ007457 Mycobacterium koreense JF271827 Corynebacterium afermentans EF107157 Mycobacterium kubicae AY373458 Mycobacterium abscessus JX154122 Mycobacterium kumamotonense JX154126 Mycobacterium aemonae AM902964 Mycobacterium kyorinense JN974461 Mycobacterium africanum AF547803 Mycobacterium lacticola HM030495 Mycobacterium agri AY438080 Mycobacterium lacticola HM030495 Mycobacterium aichiense AJ310218 Mycobacterium lacus AY438090 Mycobacterium aichiense AF547804 Mycobacterium
    [Show full text]
  • Phylogenomic Analysis of the Species of the Mycobacterium Tuberculosis
    Phylogenomic analysis of the species of the Mycobacterium tuberculosis complex demonstrates that Mycobacterium africanum, Mycobacterium bovis, Mycobacterium caprae, Mycobacterium microti and Mycobacterium pinnipedii are later heterotypic synonyms of Mycobacterium tuberculosis Marco Riojas, Katya Mcgough, Cristin Rider-Riojas, Nalin Rastogi, Manzour Hernando Hazbón To cite this version: Marco Riojas, Katya Mcgough, Cristin Rider-Riojas, Nalin Rastogi, Manzour Hernando Hazbón. Phy- logenomic analysis of the species of the Mycobacterium tuberculosis complex demonstrates that My- cobacterium africanum, Mycobacterium bovis, Mycobacterium caprae, Mycobacterium microti and Mycobacterium pinnipedii are later heterotypic synonyms of Mycobacterium tuberculosis. Inter- national Journal of Systematic and Evolutionary Microbiology, Microbiology Society, 2018, 68 (1), pp.324-332. 10.1099/ijsem.0.002507. pasteur-01986654 HAL Id: pasteur-01986654 https://hal-riip.archives-ouvertes.fr/pasteur-01986654 Submitted on 18 Jan 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. RESEARCH ARTICLE Riojas et al., Int J Syst Evol Microbiol 2018;68:324–332 DOI 10.1099/ijsem.0.002507 Phylogenomic analysis of the species of the Mycobacterium tuberculosis complex demonstrates that Mycobacterium africanum, Mycobacterium bovis, Mycobacterium caprae, Mycobacterium microti and Mycobacterium pinnipedii are later heterotypic synonyms of Mycobacterium tuberculosis Marco A.
    [Show full text]
  • Numerical Analysis of Rapidly Growing, Scotochromogenic Mycobacteria, Including Mycobacterium O Buense Sp
    INTERNATIONALJOURNAL OF SYSTEMATICBACTERIOLOGY, July 1981, p. 263-275 Vol. 31, No. 3 0020-7713/81/030263-13$02.00/0 Numerical Analysis of Rapidly Growing, Scotochromogenic Mycobacteria, Including Mycobacterium o buense sp. nov., norn. rev., Mycobacterium rhodesiae sp. nov., nom. rev., Mycobacterium aichiense sp. nov., norn. rev., Mycobacterium chubuense sp. nov., norn. rev., and Mycobacterium tokaiense sp. nov., nom. rev. MICHIO TSUKAMURA, SHOJI MIZUNO, AND SUM10 TSUKAMURA The National Chubu Hospital, Obu, Aichi, Japan 474 We performed numerical analyses of 155 strains of rapidly growing, scotochrom- ogenic mycobacteria by two different methods; in one method we used 104 characters, and in the other we used 84 characters. The following taxa appeared as distinct clusters: Myco bacterium thermoresistibile, Myco bacterium flavescens, Mycobacterium duvalii, Mycobacterium phlei, “Mycobacterium o buense,” My- co bacterium parafortuitum, Mycobacterium vaccae, Mycobacterium sphagni, “Mycobacterium aichiense,” “Mycobacterium rhodesiae,” Mycobacterium neoaurum, “Mycobacterium chubuense,” “Mycobacterium tokaiense,” and My- cobacterzum komossense (names in quotation marks are not on the Approved Lists of Bacterial Names). M. flavescens strains were divided into two subgroups, one consisting of strains isolated in Japan and the other consisting of strains isolated in Rhodesia and strains received from the American Type Culture Collection, including the type strain of M. flavescens (ATCC 14474). We found that there are many species of rapidly growing, scotochromogenic mycobacteria, and we believe that new species should be recognized and named on the basis of at least three strains. The following species appeared to be distinct from all presently named species: “Mycobacteriumgallinarum,” “Mycobacterium armen- tun,” “Mycobacterium pelpallidurn,” and “Mycobacterium taurus.” However, each of these species was proposed on the basis of only one or two strains.
    [Show full text]
  • Role of Immunotherapy in the Treatment of Tuberculosis
    ROLE OF IMMUNOTHERAPY IN THE TREATMENT OF TUBERCULOSIS MURTHY, K.J.R. VIJAYA LAKSHMI, V. and Singh, S. Bhagwan Mahavir Medical Research Centre, 10-1-1, Mahavir Marg, Hyderabad - 500 029. India. ABSTRACT Tuberculosis is caused by Mycobacterium tuberculosis, an intracellular pathogen residing in macrophages. Cell mediated immune (CMI) and delayed type of hypersensitive (DTH) responses play a pivotal role in providing protection to the host. The most important cell is the CD4 T lymphocyte, which is divided into TH1 and TH2 subsets depending on the type of cytokines produced. TH1 cells produce the cytokines interferon-gamma and interleukin-2, which are important for activa- tion of antimycobacterial activities and essential for the DTH response. Grange opines that the immune response in an individual with tuberculous infection gets locked in' to one or other pattern of response viz. TH1 or TH2 response, the latter response leading to tissue damage and progression of disease. Stanford and co-workers conducted several studies on the effectiveness of Mycobacterium vaccae, as an immunotherapeutic agent for tuberculosis. It is non-pathogenic in humans and is thought to be a powerful TH1 adjuvant. A series of small studies pointed that M. vaccae has a beneficial effect and there is enough evidence now to show that its use as an immunotherapeutic agent, as an adjunct to chemotherapy in the treatment of tuberculosis especially at a time when drug resistance is rampant, appears promising. KEY WORDS : Tuberculosis, Drug-Resistance, Immunotherapy, T Cell Responses. ROLE OF IMMUNOTHERAPY IN THE cytokines secreted by the TH1 cell are interferon- TREATMENT OF TUBERCULOSIS gamma (IFN-~,) and interleukin-2 (IL-2).
    [Show full text]
  • Opportunist Mycobacteria
    Thorax: first published as 10.1136/thx.44.6.449 on 1 June 1989. Downloaded from Thorax 1989;44:449454 Editorial Treatment of pulmonary disease caused by opportunist mycobacteria During the early 1950s it was recognised that recommended that surgical treatment for opportunist mycobacteria other than Mycobacterium tuberculosis mycobacterial infection should be given to those could cause pulmonary disease in man.' Over 30 years patients who are suitable surgical candidates.'7 The later there is no general agreement about the treatment failure of chemotherapy was often attributed to drug of patients with these mycobacterial infections. The resistance,'2 18 but the importance of prolonging the greatest controversy surrounds the treatment of in- duration of chemotherapy in opportunist mycobac- fection caused by the M aviwn-intracellulare- terial disease beyond that which would normally be scrofulaceum complex (MAIS), for which various required in tuberculosis was not appreciated. In treatments have been advocated, including chemo- several surgically treated series preoperative chemo- therapy with three23 or more' drugs or, alternatively, therapy was given on average for only four to seven surgical resection of the affected lung.78 Although the months,'3 19-22 some patients receiving as little as eight treatment of infection caused by M kansasii is less weeks of treatment before surgery.2324 In contrast, controversial there is no uniform approach to treat- chemotherapy alone, with isoniazid, p-aminosalicyclic ment. Disease caused by M xenopi has been described acid, and streptomycin for 24 months, produced by some as easy to treat with chemotherapy,9 whereas successful results in 80-100% of patients with M others have found the response to drug treatment to be kansasii infection despite reports of in vitro resistance unpredictable.'' " to these agents.2125 This diversity ofopinion and approach to treatment has arisen for two reasons.
    [Show full text]
  • A Simple and Efficient Multiplex PCR Assay for the Identification of Mycobacteriumgenus and Mycobacterium Tuberculosis Complex T
    http://dx.doi.org/10.3349/ymj.2013.54.5.1220 Original Article pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 54(5):1220-1226, 2013 A Simple and Efficient Multiplex PCR Assay for the Identification ofMycobacterium Genus and Mycobacterium tuberculosis Complex to the Species Level Yeun Kim,1 Yeonim Choi,1 Bo-Young Jeon,1 Hyunwoo Jin,1,2 Sang-Nae Cho,3 and Hyeyoung Lee1 1Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, Wonju; 2Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Busan; 3Department of Microbiology, Yonsei University College of Medicine, Seoul, Korea. Received: September 19, 2012 Purpose: The Mycobacterium tuberculosis complex comprises M. tuberculosis, Revised: October 25, 2012 M. bovis, M. bovis bacillus Calmette-Guérin (BCG) and M. africanum, and causes Accepted: October 29, 2012 tuberculosis in humans and animals. Identification of Mycobacterium spp. and M. Corresponding author: Dr. Hyeyoung Lee, tuberculosis complex to the species level is important for practical use in microbi- Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, ological laboratories, in addition to optimal treatment and public health. Materials 1 Yonseidae-gil, Wonju 220-710, Korea. and Methods: A novel multiplex PCR assay targeting a conserved rpoB sequence Tel: 82-33-760-2740, Fax: 82-33-760-2561 in Mycobacteria spp., as well as regions of difference (RD) 1 and RD8, was devel- E-mail: [email protected] oped and evaluated using 37 reference strains and 178 clinical isolates. Results: All mycobacterial strains produced a 518-bp product (rpoB), while other bacteria ∙ The authors have no financial conflicts of produced no product.
    [Show full text]
  • Nontuberculous Mycobacterial Species and Mycobacterium Tuberculosis Complex Coinfection in Patients with Pulmonary Tuberculosis in Dr
    [Downloaded free from http://www.ijmyco.org on Saturday, September 28, 2019, IP: 210.57.215.50] Original Research Article Nontuberculous Mycobacterial Species and Mycobacterium Tuberculosis Complex Coinfection in Patients with Pulmonary Tuberculosis in Dr. Soetomo Hospital, Surabaya, Indonesia Ni Made Mertaniasih1,2, Deby Kusumaningrum1,2, Eko Budi Koendhori1,2, Soedarsono3, Tutik Kusmiati3, Desak Nyoman Surya Suameitria Dewi2 Departments of 1Clinical Microbiology and 3Pulmonology, Faculty of Medicine, Airlangga University, Dr. Soetomo Hospital, Surabaya 60131, 2Institute of Tropical Disease, Airlangga University, Surabaya 60115, Indonesia Abstract Objective/Background: The aim of this study was to analyze the detection of nontuberculous mycobacterial (NTM) species derived from sputum specimens of pulmonary tuberculosis (TB) suspects. Increasing prevalence and incidence of pulmonary infection by NTM species have widely been reported in several countries with geographical variation. Materials and Methods: Between January 2014 and September 2015, sputum specimens from chronic pulmonary TB suspect patients were analyzed. Laboratory examination of mycobacteria was conducted in the TB laboratory, Department of Clinical Microbiology, Dr. Soetomo Hospital, Surabaya. Detection and identification of mycobacteria were performed by the standard culture method using the BACTEC MGIT 960 system (BD) and Lowenstein–Jensen medium. Identification of positive Mycobacterium tuberculosis complex (MTBC) was based on positive acid-fast bacilli microscopic smear, positive niacin accumulation, and positive TB Ag MPT 64 test results (SD Bioline). If the growth of positive cultures and acid-fast bacilli microscopic smear was positive, but niacin accumulation and TB Ag MPT 64 (SD Bioline) results were negative, then the isolates were categorized as NTM species. MTBC isolates were also tested for their sensitivity toward first-line anti-TB drugs, using isoniazid, rifampin, ethambutol, and streptomycin.
    [Show full text]
  • Nucleic Acid Sequences Specific for Mycobacterium Kansasii
    Europaisches Patentamt 19 European Patent Office Office europeen des brevets (n) Publication number : 0 669 402 A2 12 EUROPEAN PATENT APPLICATION @ Application number: 95301106.1 @ Int. CI.6: C12Q 1/68, // (C12Q1/68, C12R1 .32) (§) Date of filing : 21.02.95 (30) Priority : 28.02.94 US 203534 @ Inventor : Spears, Patricia A. 8605 Carol ingian Court @ Date of publication of application : Raleigh, North Carolina 27615 (US) 30.08.95 Bulletin 95/35 Inventor : Shank, Daryl D. 1213 Basil Court @ Designated Contracting States : Bel Air, Maryland 21014 (US) DE FR GB IT NL SE (74) Representative : Ruffles, Graham Keith (7i) Applicant : Becton Dickinson and Company MARKS & CLERK, One Becton Drive 57-60 Lincoln's Inn Fields Franklin Lakes, New Jersey 07417-1880 (US) London WC2A 3LS (GB) (54) Nucleic acid sequences specific for mycobacterium kansasii. (57) Oligonucleotide probes and primers which exhibit M. /ransas/f-specificity in nucleic acid hybridization assays and in nucleic acid amplifi- cation reactions. The full-length M. kan- sasff-specific sequence, identified herein as o o clone MK7, is 493 base pairs in length and has a I GC content of 63%. Several M. kansasii-spec\f\c subsequences of MK7 are also provided. The > probes and primers are useful in assays for > species-specific detection and identification of M. kansasii. oa o > >CD o > CM < CM <~> O O o> CO CO LU Jouve, 18, rue Saint-Denis, 75001 PARIS EP 0 669 402 A2 FIELD OF THE INVENTION The present invention relates to oligonucleotide probes and amplification primers, and particularly relates to oligonucleotide probes and primers which hybridize in a species-specific manner to Mycobacterium kansasii 5 nucleic acids.
    [Show full text]
  • Mycobacterium Goodii Endocarditis Following Mitral Valve Ring Annuloplasty Rohan B
    Parikh and Grant Ann Clin Microbiol Antimicrob (2017) 16:14 DOI 10.1186/s12941-017-0190-4 Annals of Clinical Microbiology and Antimicrobials CASE REPORT Open Access Mycobacterium goodii endocarditis following mitral valve ring annuloplasty Rohan B. Parikh1 and Matthew Grant2* Abstract Background: Mycobacterium goodii is an infrequent human pathogen which has been implicated in prosthesis related infections and penetrating injuries. It is often initially misidentified as a gram-positive rod by clinical microbio- logic laboratories and should be considered in the differential diagnosis. Case presentation: We describe here the second reported case of M. goodii endocarditis. Species level identification was performed by 16S rDNA (ribosomal deoxyribonucleic acid) gene sequencing. The patient was successfully treated with mitral valve replacement and a prolonged combination of ciprofloxacin and trimethoprim/sulfamethoxazole. Conclusion: Confirmation of the diagnosis utilizing molecular techniques and drug susceptibility testing allowed for successful treatment of this prosthetic infection. Keywords: Mycobacterium goodii, Endocarditis, Gene sequencing, Prostheses related infections Background appreciated at the apex, and a drain was in place for a Mycobacterium goodii is a rapidly growing non-tubercu- groin seroma related to recent left heart catheterization. lous mycobacterium (NTM) belonging to the Mycobac- He had an unsteady gait and exhibited mild left lower terium smegmatis [1] group. Its importance has become extremity weakness (4/5). His brain magnetic resonance increasingly appreciated as a pathogen over the last imaging showed multiple ring-enhancing lesions in the 20 years, with a predilection towards infecting tissues at pons and posterior fossa suggestive of septic emboli. the site of penetrating injuries. Antibacterial treatment Transthoracic echocardiography showed moderate strategies against this pathogen are diverse but reported mitral regurgitation without any vegetation.
    [Show full text]
  • Immunotherapy of TB…
    Results from Phase III, placebo-controlled, 2:1 randomized, double-blind trial of tableted TB vaccine (V7) containing 10 μg of heat-killed Mycobacterium vaccae administered daily for one month Correspondence: Aldar Bourinbaiar * Tel: +976 95130306; +1 301 476-0930 * e-mail: [email protected] Tuberculosis • 33% of people carry TB bacteria = 2.5 billion • Every second, a person becomes ill with TB • Every year 10 mln people develop TB and 2 mln die • Drug-resistant TB poised to become global pandemic • Less than 3% of drug-resistant TB is treated today Th-1 cells = IFN-ɣ, IL-2, GM-CSF, IFN-ɑ, TNF-ɑ, IL-12, IL-18 Th-2 cells = IL-4, IL-5, IL-13 Th-17 cells = IL-6, IL-17, IL-22, TNF-ɑ Treg cells = IL-10, TGF-ɓ B cells = IFN-ɑ, IL-1ɓ, IL-12 Monocytes = IL-8, IL-18, TNF-ɑ State-of-the-art: immunology of TB – a great deal of information gathered but… can't see the forest through the trees When this vast knowledge was applied to immunotherapy of TB…. it failed… It also resulted in negative attitude toward immunotherapy • IL-2 (increased bacterial load) • IL-12 (no effect) • GM-CSF (clearance not confirmed) • IFN-ɣ (irreproducible, no effect) • IFN-ɑ (negative outcome) • anti-TNF-ɑ (negative outcome) • Thalidomide (negative outcome) • Corticosteroids (irreproducible, negative effect) Paradoxes of Tuberculosis • 1/3 of world population (~2.5bln) have latent M. tuberculosis • Yet only about 10 Million people (0.004%) develop TB • M. tuberculosis is in symbiotic relationship with the host • In some cases it’s even beneficial (asthma, cancer) • M.
    [Show full text]
  • An Abstract of the Dissertation of Melanie J. Harriff
    AN ABSTRACT OF THE DISSERTATION OF MELANIE J. HARRIFF for the degree of Doctor of Philosophy in Molecular and Cellular Biology presented on June 8, 2007. Title: Mechanisms for the Interaction of Environmental Mycobacteria with Host Cells Abstract approved: Luiz E. Bermudez Michael L. Kent Environmental mycobacteria are important opportunistic pathogens for many hosts, including humans, cattle, and fish. Two well-studied species are Mycobacterium avium subsp. avium, a significant cause of disseminated bacterial disease in patients with AIDS, and Mycobacterium avium subsp. paratuberculosis, the cause of Johne’s disease in cattle. Many other species that are considerable sources of infections in fish, such as Mycobacterium chelonae and Mycobacterium marinum, also have zoonotic potential. To gain knowledge about the invasion of epithelial cells by environmental mycobacteria, selected genes and proteins involved in the uptake of M. avium by HEp-2 cells were analyzed by a variety of methods. Two transcriptional regulators (MAV_3679 and MAV_5138) were identified as being involved in invasion. A mycobacterial protein (CipA) with an amino acid sequence suggestive of an ability to be a part of the scaffolding complex that forms during cell signaling leading to actin polymerization was found to putatively interact with host cell Cdc42. Fusion of CipA to GFP, expressed in Mycobacterium smegmatis, revealed that CipA localizes to a structure on the surface of bacteria approaching HEp-2 cells. To establish whether species of environmental mycobacteria isolated from different hosts use similar mechanisms to M. avium for interaction with the mucosa, and for survival in macrophages, assays to determine invasion and replication were performed in different cell types, and a custom DNA microarray containing probes for known mycobacterial virulence determinants was developed.
    [Show full text]
  • Mycobacterium Vaccae Has Been Given to Patients with Prostate Cancer and Melanoma Indicating a Possible Beneficial Effect on Disease Activity in Such Patients
    British Journal of Cancer (2000) 83(7), 853–857 © 2000 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1401, available online at http://www.idealibrary.com on A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma MER O’Brien1,2, A Saini1, IE Smith1, A Webb1, K Gregory1, R Mendes1,3, C Ryan2, K Priest1, KV Bromelow3, RD Palmer4, N Tuckwell6, DA Kennard5 and BE Souberbielle1,3 1Royal Marsden Hospital NHS Trust, Sutton, Surrey, SM2 5PT; 2Kent Cancer Centre, Maidstone, ME16 9QQ; 3Dept of Molecular Medicine, King’s College, SE5 9NU, London, 4Department of Bacteriology, University College London Medical School, W1P 6DB; 5SR Pharma, 26th Floor, Centre Point, 103 New Oxford Street, London WC1A 1DD, UK Summary Mycobacterial preparations have been used with limited success against cancer apart from superficial bladder cancer. Recently, a therapeutic vaccine derived from Mycobacterium vaccae has been given to patients with prostate cancer and melanoma indicating a possible beneficial effect on disease activity in such patients. We have recently initiated a series of randomized studies to test the feasibility and toxicity of combining a preparation of heat-killed Mycobacterium vaccae (designated SRL172) with a multidrug chemotherapy regimen to treat patients with inoperable non-small cell lung cancer (NSCLC) and mesothelioma. 28 evaluable patients with previously untreated symptomatic NSCLC and mesothelioma were randomized to receive either 3 weekly intravenous combination chemotherapy alone, or chemotherapy given with monthly intra-dermal injections of SRL172. Safety and tolerability were scored by common toxicity criteria and efficacy was evaluated by survival of patients and by tumour response assessed by CT scanning.
    [Show full text]